{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:42:09Z","timestamp":1789753329974,"version":"4.0.1"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Ketamine was developed as an anesthetic. Esketamine is the isolated S-enantiomer of racemic ketamine. They provide new avenues for the treatment of depression, especially treatment-resistant depression. Considering differences in the pharmacokinetics and hormonal status of ketamine in patients of different genders, sex-based differences in esketamine adverse drug events (ADE) may also be observed. This study presents data mining and safety analysis of adverse events of ketamine and esketamine between genders, promoting the individualization of clinical practice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Adverse drug reactions to ketamine and esketamine reported between the first quarter of 2004 and the second quarter of 2023 in the U.S. Food and Drug Administration on Adverse Event Reporting System (FAERS) were extracted. Thereafter, the reporting odds ratio (ROR) with 95% confidence interval (CI) was calculated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 2907 female reports and 1634 male reports on esketamine were included in the analysis. ROR mining showed that completed suicide, decreased therapeutic product effects, urinary retention, and hypertension were common in men. Additionally, 552 female and 653 male ketamine reports were recorded. ROR mining revealed that toxicity to various agents, bradycardia, cystitis and agitation, were more likely to occur in men, whereas women were more likely to develop suicidal ideation, increased transaminase levels, sclerosing cholangitis, and sterile pyuria.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The adverse events of esketamine and ketamine differ across genders, which should be considered in clinical practice to provide individualized treatment.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1329436","type":"journal-article","created":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T04:31:40Z","timestamp":1720758700000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Comparing the adverse effects of ketamine and esketamine between genders using FAERS data"],"prefix":"10.3389","volume":"15","author":[{"given":"Xinxia","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongdong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e204693","DOI":"10.1001\/jamanetworkopen.2020.4693","article-title":"Association of ketamine with psychiatric symptoms and implications for its therapeutic use and for understanding schizophrenia: a systematic review and meta-analysis","volume":"3","author":"Beck","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"B2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1176\/appi.focus.17105","article-title":"Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study","volume":"17","author":"Canuso","year":"2019","journal-title":"Focus Am Psychiatr. Publ."},{"key":"B3","doi-asserted-by":"publisher","first-page":"466","DOI":"10.12809\/hkmj209194","article-title":"Systematic review and meta-analysis of ketamine-associated uropathy","volume":"28","author":"Chan","year":"2022","journal-title":"Hong Kong Med. J."},{"key":"B4","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.pbb.2019.04.008","article-title":"Comparison of antidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine","volume":"181","author":"Chang","year":"2019","journal-title":"Pharmacol. Biochem. Behav."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1038\/s41386-020-0714-z","article-title":"Sex-specific neurobiological actions of prophylactic (R,S)-ketamine, (2R,6R)-hydroxynorketamine, and (2S,6S)-hydroxynorketamine","volume":"45","author":"Chen","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"587","DOI":"10.2147\/ndt.S401032","article-title":"Acute effects of intravenous sub-anesthetic doses of ketamine and intranasal inhaled esketamine on suicidal ideation: a systematic review and meta-analysis","volume":"19","author":"Chen","year":"2023","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1007\/s11096-022-01472-x","article-title":"Data mining for adverse drug reaction signals of daptomycin based on real-world data: a disproportionality analysis of the US Food and Drug Administration adverse event reporting system","volume":"44","author":"Chen","year":"2022","journal-title":"Int. J. Clin. Pharm."},{"key":"B8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1747-597x-9-39","article-title":"Gender differences in subjective discontinuation symptoms associated with ketamine use","volume":"9","author":"Chen","year":"2014","journal-title":"Subst. Abuse Treat. Prev. Policy"},{"key":"B9","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.schres.2018.02.049","article-title":"Similar psychotic and cognitive profile between ketamine dependence with persistent psychosis and schizophrenia","volume":"199","author":"Cheng","year":"2018","journal-title":"Schizophr. Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.euroneuro.2023.04.011","article-title":"Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: a viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study","volume":"74","author":"Chiappini","year":"2023","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1007\/s40264-021-01120-9","article-title":"Repeated or continuous medically supervised ketamine administration associated with hepatobiliary adverse events: a retrospective case series","volume":"44","author":"Cotter","year":"2021","journal-title":"Drug Saf."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.jagp.2023.06.016","article-title":"Investigating the effectiveness and tolerability of intranasal esketamine among older adults with treatment-resistant depression (TRD): a post-hoc analysis from the REAL-ESK study group","volume":"31","author":"D'Andrea","year":"2023","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"B13","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.jad.2023.12.038","article-title":"The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: a post-hoc analysis of pooled real-world data","volume":"348","author":"D'Andrea","year":"2024","journal-title":"J. Affect Disord."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1214972","DOI":"10.3389\/fnins.2023.1214972","article-title":"Central nervous system-related safety and tolerability of add-on ketamine to standard of care treatment in treatment-resistant psychotic depression in patients with major depressive disorder and bipolar disorder","volume":"17","author":"Ga\u0142uszko-W\u0229gielnik","year":"2023","journal-title":"Front. Neurosci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000510703","article-title":"Post-marketing safety concerns with esketamine: a disproportionality analysis of spontaneous reports submitted to the FDA adverse event reporting system","volume":"90","author":"Gastaldon","year":"2021","journal-title":"Psychother. Psychosom."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.3760\/cma.j.cn112338-20201208-01386","article-title":"Prescription sequence symmetry analysis in pharmacoepidemiology: a systematic review","volume":"42","author":"He","year":"2021","journal-title":"Zhonghua Liu Xing Bing Xue Za Zhi"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-023-01732-5","article-title":"The correlation of Esketamine with specific adverse events: a deep dive into the FAERS database","author":"Jiang","year":"2023","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci"},{"key":"B18","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1177\/2168479017728986","article-title":"An alternative to disproportionality: a frequency-based method for pharmacovigilance data mining","volume":"52","author":"Jokinen","year":"2018","journal-title":"Ther. Innov. Regul. Sci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s00737-021-01185-6","article-title":"Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials","volume":"25","author":"Jones","year":"2022","journal-title":"Arch. Womens Ment. Health"},{"key":"B20","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jclinepi.2021.01.015","article-title":"Adverse drug reaction risks obtained from meta-analyses and pharmacovigilance disproportionality analyses are correlated in most cases","volume":"134","author":"Khouri","year":"2021","journal-title":"J. Clin. Epidemiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJMp1903305","article-title":"Esketamine for treatment-resistant depression - first FDA-approved antidepressant in a new class","volume":"381","author":"Kim","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1080\/14740338.2023.2243220","article-title":"Gender differences in adverse events related to Osimertinib: a real-world pharmacovigilance analysis of FDA adverse event reporting system","volume":"23","author":"Li","year":"2023","journal-title":"Expert Opin. Drug Saf."},{"key":"B23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s40264-015-0351-3","article-title":"An empirical approach to explore the relationship between measures of disproportionate reporting and relative risks from analytical studies","volume":"39","author":"Maci\u00e1-Mart\u00edNEZ","year":"2016","journal-title":"Drug Saf."},{"key":"B24","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/bdi.13296","article-title":"Treating bipolar depression with esketamine: safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depression","volume":"25","author":"Martinotti","year":"2023","journal-title":"Bipolar Disord."},{"key":"B25","doi-asserted-by":"publisher","first-page":"109357","DOI":"10.1016\/j.neuropharm.2022.109357","article-title":"Intranasal (R, S)-ketamine delivery induces sustained antidepressant effects associated with changes in cortical balance of excitatory\/inhibitory synaptic activity","volume":"225","author":"Nguyen","year":"2023","journal-title":"Neuropharmacology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1080\/14740338.2022.2066651","article-title":"Long-term safety of ketamine and esketamine in treatment of depression","volume":"21","author":"Nikayin","year":"2022","journal-title":"Expert Opin. Drug Saf."},{"key":"B27","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3390\/life10080138","article-title":"Comparison of data mining methods for the signal detection of adverse drug events with a hierarchical structure in postmarketing surveillance","volume":"10","author":"Park","year":"2020","journal-title":"Life (Basel)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/s41386-019-0570-x","article-title":"Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression","volume":"45","author":"Phillips","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1056\/NEJMoa2304145","article-title":"Esketamine nasal spray versus quetiapine for treatment-resistant depression","volume":"389","author":"Reif","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1176\/appi.ajp.2019.19040423","article-title":"A word to the wise about intranasal esketamine","volume":"176","author":"Schatzberg","year":"2019","journal-title":"Am. J. Psychiatry"},{"key":"B31","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/s2215-0366(17)30272-9","article-title":"Side-effects associated with ketamine use in depression: a systematic review","volume":"5","author":"Short","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"B32","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/s41586-022-04993-7","article-title":"Dual action of ketamine confines addiction liability","volume":"608","author":"Simmler","year":"2022","journal-title":"Nature"},{"key":"B33","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.biopsych.2015.10.018","article-title":"Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study","volume":"80","author":"Singh","year":"2016","journal-title":"Biol. Psychiatry"},{"key":"B34","first-page":"585","article-title":"Short-term ketamine administration in treatment-resistant depression: focus on cardiovascular safety","volume":"31","author":"Szarmach","year":"2019","journal-title":"Psychiatr. Danub"},{"key":"B35","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1080\/14740338.2021.1949454","article-title":"Harm related to recreational ketamine use and its relevance for the clinical use of ketamine. A systematic review and comparison study","volume":"21","author":"van Amsterdam","year":"2022","journal-title":"Expert Opin. Drug Saf."},{"key":"B36","doi-asserted-by":"publisher","first-page":"341","DOI":"10.9758\/cpn.2021.19.2.341","article-title":"Rapid onset of intranasal esketamine in patients with treatment resistant depression and major depression with suicide ideation: a meta-analysis","volume":"19","author":"Wang","year":"2021","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1056\/NEJMra1410052","article-title":"Sterile pyuria","volume":"372","author":"Wise","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e632","DOI":"10.1038\/tp.2015.136","article-title":"R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects","volume":"5","author":"Yang","year":"2015","journal-title":"Transl. Psychiatry"},{"key":"B39","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s44192-022-00012-3","article-title":"Ketamine treatment for depression: a review","volume":"2","author":"Yavi","year":"2022","journal-title":"Discov. Ment. Health"},{"key":"B40","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.biopsych.2012.03.004","article-title":"Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression","volume":"72","author":"Zarate","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"B41","doi-asserted-by":"publisher","first-page":"109219","DOI":"10.1016\/j.neuropharm.2022.109219","article-title":"Arketamine, a new rapid-acting antidepressant: a historical review and future directions","volume":"218","author":"Zhang","year":"2022","journal-title":"Neuropharmacology"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1329436\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T04:31:45Z","timestamp":1720758705000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1329436\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,12]]},"references-count":41,"alternative-id":["10.3389\/fphar.2024.1329436"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1329436","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,12]]},"article-number":"1329436"}}